Aggressive Lymphoma
Oncology·MeSH: Lymphoma, Large B-Cell, Diffuse
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| KT-333 | Kymera Therapeutics, Inc. (KYMR) |
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| ifx-3.0 | TuHURA Biosciences, Inc./NV (HURA) |
Compare drugs
Frequently asked questions
How many drugs are in development for Aggressive Lymphoma?
BioSniper tracks 2 drugs in development for Aggressive Lymphoma across 2 companies.
How many clinical trials target Aggressive Lymphoma?
There are 1 clinical trial targeting Aggressive Lymphoma tracked by BioSniper.
What is the prevalence of Aggressive Lymphoma?
The estimated prevalence of Aggressive Lymphoma is approximately 56.0 per 100,000 population.
Deep-dive into Aggressive Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis